Exactics is an innovative precision biotech startup, pioneering a new revolution in consumer healthcare. The company’s goal is to create diagnostic kits that arms everyone with a better ability to test and treat. To start, the biotech company is directing its efforts at at-home screening of Lyme disease. This program’s goal is to provide people with the resources they need so they can proactively track their health.
The startup’s progress has been marked by their roadmap development for diagnostic kits aimed at other consumer illnesses, cementing its pledge to expand consumer diagnostics. Among its most impressive innovations is a gene-editing CRISPR kit meant to eradicate viruses. This revolutionary kit allows installations of “universal donor” markers, while perfusing organs with specialized fluids outside of the body. This new-age feature has the potential to massively increase successful organ transplant rates.
The startup’s ventures were highlighted during TechCrunch’s prestigious Startup Battlefield pitch contest, which attracts thousands of applicants annually. Of this rigorous cohort, just 200 of the best and brightest competitors are chosen to actually compete in the event. These 20 startups will have the opportunity to display their innovations on a much bigger stage. They’ll be competing for our legendary, highly-sought-after Startup Battlefield Cup and a cash prize of $100,000.
The next TC Startup Battlefield powered by the world-famous TC Startup Alley will be October 13-15, 2026 in San Francisco. While the top contenders will compete for recognition and funding, the remaining 180 startups will engage in their own pitch competition, further showcasing the breadth of innovation within the biotech sector.
Exactics’ advancements in consumer diagnostics and organ transplantation technologies highlight the potential impact of startups in addressing critical healthcare challenges. The dynamic startup landscape, including companies like Exactics at the forefront, is paving the way to a more personalized, effective, and safer medical future for consumers.
Leave a Reply